Search Within

Alexander Meyer Lesokhin

Formats
  1. Meeting Abstract (243)
  2. Journal Article (97)
  3. Research Letter (10)
  4. Review (7)
  5. Correspondence (3)
  6. Book Section (2)
  7. Editorial (2)
Groups
  1. Center for Hematologic Malignancies (364)
  2. Department of Medicine (364)
  3. Hematologic Malignancies Research (364)
  4. Hematologic Malignancies, Division of (364)
  5. Myeloma (364)
  6. Survivorship Research (212)

More Groups

People
  1. Hani Hassoun (193)
  2. Heather Landau (177)
  3. Sergio Giralt (174)
  4. David Chung (168)
  5. Neha Korde (162)
  6. Sham Mailankody (159)

More People

Years
  1. 2025 (3)
  2. 2024 (44)
  3. 2023 (77)
  4. 2022 (51)
  5. 2021 (31)
  6. 2020 (18)

More Years

Publications
  1. Blood (132)
  2. Clinical Lymphoma, Myeloma and Leukemia (57)
  3. Journal of Clinical Oncology (40)
  4. Biology of Blood and Marrow Transplantation (13)
  5. Leukemia and Lymphoma (12)
  6. Blood Advances (10)

More Publications

Publishers
  1. American Society of Hematology (142)
  2. Elsevier Inc. (78)
  3. American Society of Clinical Oncology (40)
  4. Nature Publishing Group (23)
  5. American Association for Cancer Research (14)
  6. Taylor & Francis Group (12)

More Publishers

Results (364)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Recycling is “bad to the bone” in patients with myeloma
    Editorial

    Miller, K. C.; Lesokhin, A. M.
    Blood (2025)

    Fulltext@MSK | Save
  • Phase I trial of MCARH109, a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor T-cell therapy for multiple myeloma: An updated analysis
    Journal Article

    Jurgens, E. M.; Firestone, R. S.; Chaudhari, J.; Hosszu, K.; Devlin, S. M.; Shah, U. A.; Landa, J.; McAvoy, D. P.; Lesokhin, A. M.; Korde, N.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Evaluating serum free light chain ratio as a biomarker in multiple myeloma
    Journal Article

    Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A. M.; Hassoun, H.; Lu, S. X.; Patel, D.; Shah, U. A.; Tan, C. R.; more...
    Haematologica (2025)

    Fulltext@MSK | Save
  • Cevostamab in patients with heavily pretreated relapsed/refractory multiple myeloma (RRMM): Updated results from an ongoing phase i study demonstrate clinically meaningful activity and manageable safety and inform the doses and regimen for combination studies
    Meeting Abstract

    Richter, J.; Thomas, S. K.; Krishnan, A. Y.; Laubach, J. P.; Cohen, A. D.; Trudel, S.; Costa, L. J.; Bahlis, N. J.; Forsberg, P. A.; Kaedbey, R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Genomic complexity correlates with the degree of marrow independence of malignant plasma cells in the context of extramedullary disease
    Meeting Abstract

    Maclachlan, K. H.; Garces, J. J.; Shekarkhand, T.; Rajeeve, S.; Hashmi, H.; Hassoun, H.; Hultcrantz, M.; Korde, N.; Tan, C. R.; Mailankody, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Defining the rates of cytokine release syndrome associated with talquetamab step-up doses
    Meeting Abstract

    Hamadeh, I. S.; Shekarkhand, T.; Rueda, C.; Firestone, R. S.; Wang, A. X.; Korde, N.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Real-world safety and early efficacy of talquetamab in patients with heavily-pretreated relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B. A.; Tan, C. R.; Shekarkhand, T.; Firestone, R. S.; Jurgens, E. M.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; Rajeeve, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Comparison of acute kidney injury in patients with relapsed or refractory multiple myeloma following CAR T-cell and bispecific antibody therapies
    Meeting Abstract

    Nishimura, N.; Mailankody, S.; Nemirovsky, D.; Derkach, A.; Costa, B. A.; Farzana, T.; Shaikh, A.; Latcha, S.; Gutgarts, V.; Jurgens, E. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Body mass index trajectory during triplet induction therapy: Clinical implications in newly diagnosed multiple myeloma
    Meeting Abstract

    Thirugnanasambandam, R. P.; Firestone, R. S.; Derkach, A.; Furberg, H.; Shekarkhand, T.; Rueda, C.; Maclachlan, K. H.; Hultcrantz, M.; Mailankody, S.; Patel, D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Infectious complications during treatment with commercial CAR T-cell therapy and bispecific antibodies for relapsed/refractory multiple myeloma
    Meeting Abstract

    Jurgens, E. M.; Shekarkhand, T.; Farzana, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; Firestone, R. S.; Nishimura, N.; Miller, K.; Costa, B. A.; more...
    Blood (2024)

    Fulltext@MSK | Save